<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.1/dist/css/bootstrap.min.css" rel="stylesheet">
    <style>
        body{background-color:slategrey};
    </style>
  </head>
<body>
<div class="container" class="mt-10">

<div class="row justify-content-start">
    
    <div class="col-6 mb-1"><img class="img-fluid" src="table.001.dbg.png"/></div>
    
    <div class="col-6 mb-1"><img class="img-fluid" src="table.002.dbg.png"/></div>
    
    <div class="col-6 mb-1"><img class="img-fluid" src="table.003.dbg.png"/></div>
    
    <div class="col-6 mb-1"><img class="img-fluid" src="table.004.dbg.png"/></div>
    
    <div class="col-6 mb-1"><img class="img-fluid" src="table.005.dbg.png"/></div>
    
    <div class="col-6 mb-1"><img class="img-fluid" src="table.006.dbg.png"/></div>
    
    <div class="col-6 mb-1"><img class="img-fluid" src="table.007.dbg.png"/></div>
    
</div>


    <table class="row table table-bordered" width="500px">
        <tr>
            <td style="background:lightblue" colspan="6">Table 1. Structure-Activity Relationships (SAR) of C-3'-6 Substituted Analogues (19, 20, 26, and 27)a,b,c NH2 OH HO HO</td>
        </tr>
        
        <tr>
            
            <td>compound</td>
            
            <td>2</td>
            
            <td>19</td>
            
            <td>20</td>
            
            <td>26</td>
            
            <td>27</td>
            
        </tr>
        
        <tr>
            
            <td>R =</td>
            
            <td>H</td>
            
            <td>Me</td>
            
            <td>ethynyl</td>
            
            <td>vinyl</td>
            
            <td>Et</td>
            
        </tr>
        
        <tr>
            
            <td>human CD73a</td>
            
            <td>100  39d</td>
            
            <td>51</td>
            
            <td>1.7  0.22e</td>
            
            <td>103</td>
            
            <td>200</td>
            
        </tr>
        
        <tr>
            
            <td>IC50 (nM)</td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>human Cell</td>
            
            <td>434</td>
            
            <td>169</td>
            
            <td>2.8  0.41f</td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>surfaceb IC50 (nM)</td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>human plasma</td>
            
            <td></td>
            
            <td></td>
            
            <td>5.6  0.24d</td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>CD73c IC50 (nM)</td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>cLog P</td>
            
            <td>0.37</td>
            
            <td>0.15</td>
            
            <td>0.74</td>
            
            <td>0.39</td>
            
            <td>0.67</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="6"></td>
        </tr>
    </table>
    <div class="w-100"></div>

    <table class="row table table-bordered" width="500px">
        <tr>
            <td style="background:lightblue" colspan="6">Table 2. SAR Summary of C-3'-6-Alkyne Analogues (29-30)a,b, NH2 HO R HO`</td>
        </tr>
        
        <tr>
            
            <td>Compd</td>
            
            <td>R1</td>
            
            <td>R2</td>
            
            <td>Human CD73 IC50a (nM)</td>
            
            <td>Human plasma CD73 IC50b (nM)</td>
            
            <td>Rat iv CLc (mL/min/kg)</td>
            
        </tr>
        
        <tr>
            
            <td>20</td>
            
            <td>Bn</td>
            
            <td><img width="39" src="table.002.r.592_480_117_40.png"/></td>
            
            <td>1.7</td>
            
            <td>5.6</td>
            
            <td>13</td>
            
        </tr>
        
        <tr>
            
            <td>29</td>
            
            <td>Bn</td>
            
            <td>Me-=</td>
            
            <td>1.0</td>
            
            <td>1.6</td>
            
            <td>9.9</td>
            
        </tr>
        
        <tr>
            
            <td>30</td>
            
            <td>Bn</td>
            
            <td><img width="39" src="table.002.r.592_718_117_40.png"/></td>
            
            <td>0.5</td>
            
            <td>1.5</td>
            
            <td>54</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="6">The inhibitory actiyity was evaluated against recombinant human CD73 (0.0S nM) using a malachite green assay. A lower CD73 enzym concentration level was applied to accurately assess the inhibitory activity of the more potent new analogues. Inhibition of CD73 in plasma wa measured using LC/MS to assess the conversion of ISN.-AMP into ISN--ADO. cRat clearance was determined from iv dosing at a 1 mg/kg dose</td>
        </tr>
    </table>
    <div class="w-100"></div>

    <table class="row table table-bordered" width="500px">
        <tr>
            <td style="background:lightblue" colspan="6">Table 3. SAR Summary of a-Alkyl Malonic Acid Analogues 34a-ja, NH2 HO</td>
        </tr>
        
        <tr>
            
            <td>Compd</td>
            
            <td>R</td>
            
            <td>Human CD73 IC50 (nM)</td>
            
            <td>Compd</td>
            
            <td></td>
            
            <td>Human CD73 IC50 (nM</td>
            
        </tr>
        
        <tr>
            
            <td>20</td>
            
            <td><img width="43" src="table.003.r.455_478_131_98.png"/></td>
            
            <td>1.7 a</td>
            
            <td>34e</td>
            
            <td><img width="52" src="table.003.r.1110_478_156_98.png"/></td>
            
            <td>6 a</td>
            
        </tr>
        
        <tr>
            
            <td>31</td>
            
            <td>H</td>
            
            <td>58 b</td>
            
            <td>34f</td>
            
            <td><img width="52" src="table.003.r.1110_656_156_98.png"/></td>
            
            <td>5 a</td>
            
        </tr>
        
        <tr>
            
            <td>34a</td>
            
            <td>Et</td>
            
            <td>24 a</td>
            
            <td>34g</td>
            
            <td><img width="52" src="table.003.r.1110_834_156_98.png"/></td>
            
            <td>9 a</td>
            
        </tr>
        
        <tr>
            
            <td>34b</td>
            
            <td><img width="43" src="table.003.r.455_1012_131_99.png"/></td>
            
            <td>20 a</td>
            
            <td>34h</td>
            
            <td><img width="52" src="table.003.r.1110_1012_156_99.png"/></td>
            
            <td>13 a</td>
            
        </tr>
        
        <tr>
            
            <td>34c</td>
            
            <td><img width="43" src="table.003.r.455_1164_131_99.png"/></td>
            
            <td>7 b</td>
            
            <td>34i</td>
            
            <td><img width="52" src="table.003.r.1110_1164_156_99.png"/></td>
            
            <td>8 a</td>
            
        </tr>
        
        <tr>
            
            <td>34d</td>
            
            <td><img width="43" src="table.003.r.455_1343_131_98.png"/></td>
            
            <td>1.8 a</td>
            
            <td>34j</td>
            
            <td><img width="52" src="table.003.r.1110_1343_156_98.png"/></td>
            
            <td>4 a</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="6">The inhibitory activity was evaluated against recombinant human CD73 (0.05 nM) using a malachite green assay. The inhibitory activity was valuated against recombinant human CD73 (0.5 nM) using a malachite green assay. A lower CD73 enzyme concentration level was applied tc accurately assess the inhibitory activity of the more potent new analogues.</td>
        </tr>
    </table>
    <div class="w-100"></div>

    <table class="row table table-bordered" width="500px">
        <tr>
            <td style="background:lightblue" colspan="7">Table 4. SAR Summary of Analogues 39a-l and 41 with Adenine Ring Modificationa,b,c R HO Human CD73</td>
        </tr>
        
        <tr>
            
            <td>Compd</td>
            
            <td>R</td>
            
            <td>x</td>
            
            <td>cLogP</td>
            
            <td>IC50a (nM)</td>
            
            <td>CD73 IC50b (nM</td>
            
            <td>(mL/min/kg</td>
            
        </tr>
        
        <tr>
            
            <td>20</td>
            
            <td>NH2</td>
            
            <td>N</td>
            
            <td>0.74</td>
            
            <td>1.7</td>
            
            <td>5.6</td>
            
            <td>13</td>
            
        </tr>
        
        <tr>
            
            <td>39a</td>
            
            <td>NHMe</td>
            
            <td>N</td>
            
            <td>1.57</td>
            
            <td>6</td>
            
            <td>15.5</td>
            
            <td>10</td>
            
        </tr>
        
        <tr>
            
            <td>39b</td>
            
            <td>NHEt</td>
            
            <td>N</td>
            
            <td>2.10</td>
            
            <td>1</td>
            
            <td>6.5</td>
            
            <td>7.8</td>
            
        </tr>
        
        <tr>
            
            <td>39c</td>
            
            <td><img width="44" src="table.004.r.435_727_133_100.png"/></td>
            
            <td>N</td>
            
            <td>2.41</td>
            
            <td>1.7</td>
            
            <td>50</td>
            
            <td>1.4</td>
            
        </tr>
        
        <tr>
            
            <td>39d</td>
            
            <td><img width="44" src="table.004.r.435_873_133_54.png"/></td>
            
            <td>N</td>
            
            <td>2.54</td>
            
            <td>0.8</td>
            
            <td>11.5</td>
            
            <td>3.7</td>
            
        </tr>
        
        <tr>
            
            <td>39e</td>
            
            <td><img width="44" src="table.004.r.435_974_133_69.png"/></td>
            
            <td>N</td>
            
            <td>3.02</td>
            
            <td>1</td>
            
            <td>>100</td>
            
            <td>6.3</td>
            
        </tr>
        
        <tr>
            
            <td>39f</td>
            
            <td><img width="44" src="table.004.r.435_1077_133_96.png"/></td>
            
            <td>N</td>
            
            <td>3.32</td>
            
            <td>2</td>
            
            <td>917</td>
            
            <td>1.0</td>
            
        </tr>
        
        <tr>
            
            <td>39g</td>
            
            <td><img width="44" src="table.004.r.435_1204_133_95.png"/></td>
            
            <td>N</td>
            
            <td>3.32</td>
            
            <td>1</td>
            
            <td>208</td>
            
            <td>9.2</td>
            
        </tr>
        
        <tr>
            
            <td>39h</td>
            
            <td><img width="44" src="table.004.r.435_1338_133_64.png"/></td>
            
            <td>N</td>
            
            <td>0.80</td>
            
            <td>2</td>
            
            <td>7.2</td>
            
            <td>7.5</td>
            
        </tr>
        
        <tr>
            
            <td>39i</td>
            
            <td><img width="44" src="table.004.r.435_1440_133_69.png"/></td>
            
            <td>N</td>
            
            <td>1.62</td>
            
            <td>1.1</td>
            
            <td>16</td>
            
            <td>18</td>
            
        </tr>
        
        <tr>
            
            <td>39j</td>
            
            <td><img width="44" src="table.004.r.435_1544_133_88.png"/></td>
            
            <td>N</td>
            
            <td>0.59</td>
            
            <td>0.6</td>
            
            <td>5.4</td>
            
            <td>17</td>
            
        </tr>
        
        <tr>
            
            <td></td>
            
            <td>w</td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td></td>
            
            <td>Me</td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>39k</td>
            
            <td><img width="44" src="table.004.r.435_1723_133_67.png"/></td>
            
            <td>c</td>
            
            <td>3.20</td>
            
            <td>2.0</td>
            
            <td>160</td>
            
            <td>0.91</td>
            
        </tr>
        
        <tr>
            
            <td>391</td>
            
            <td>MeN Me S</td>
            
            <td>c</td>
            
            <td>2.48</td>
            
            <td>2.1</td>
            
            <td>41</td>
            
            <td>5.9</td>
            
        </tr>
        
        <tr>
            
            <td>41</td>
            
            <td><img width="44" src="table.004.r.435_1927_133_87.png"/></td>
            
            <td>N</td>
            
            <td>2.66</td>
            
            <td>0.3</td>
            
            <td>136</td>
            
            <td></td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="7">aThe inhibitory activity was evaluated against recombinant human CD73 (0.05 nM) using a malachite green assay. Inhibition of CD73 in plasm was measured using LC/MS to assess the conversion of 1sNs-AMP into 1Ns-ADO. Rat clearance was determined from iv dosing at a 1 mg/kg dose.</td>
        </tr>
    </table>
    <div class="w-100"></div>

    <table class="row table table-bordered" width="500px">
        <tr>
            <td style="background:lightblue" colspan="7">Table 5. SAR Summary of 4-Substituted Benzylic Analogues (44a, 44b, and 47-49)a,b, NH2 HO R =</td>
        </tr>
        
        <tr>
            
            <td>Compound</td>
            
            <td>20</td>
            
            <td>44a</td>
            
            <td>44b</td>
            
            <td>47</td>
            
            <td>48</td>
            
            <td>49</td>
            
        </tr>
        
        <tr>
            
            <td>Human CD73 IC50a (nM)</td>
            
            <td>1.7  0.22 d</td>
            
            <td>0.30</td>
            
            <td>0.20</td>
            
            <td>0.10</td>
            
            <td>0.26</td>
            
            <td>0.17  0.02 f</td>
            
        </tr>
        
        <tr>
            
            <td>Human plasma CD73 IC50b (nM)</td>
            
            <td>5.6  0.24 c</td>
            
            <td>15.6</td>
            
            <td>2.8</td>
            
            <td>0.38</td>
            
            <td>0.26</td>
            
            <td>0.38  0.11 f</td>
            
        </tr>
        
        <tr>
            
            <td>IC50 fold shift</td>
            
            <td>3.3</td>
            
            <td>52</td>
            
            <td>14</td>
            
            <td>3.8</td>
            
            <td>1</td>
            
            <td>2.2</td>
            
        </tr>
        
        <tr>
            
            <td>Rat iv CLc (mL/min/kg)</td>
            
            <td>13</td>
            
            <td>64</td>
            
            <td>2.9</td>
            
            <td></td>
            
            <td></td>
            
            <td>19</td>
            
        </tr>
        
        <tr>
            
            <td>cLogP</td>
            
            <td>0.74</td>
            
            <td>2.62</td>
            
            <td>1.57</td>
            
            <td>0.12</td>
            
            <td>1.26</td>
            
            <td>-0.16</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="7">The inhibitory activity was evaluated against recombinant human CD73 (0.05 nM) using a malachite green assay. Inhibition of CD73 in plasm was measured using LC/MS to assess the conyersion of ISNs-AMP into ISNs-ADO. Rat clearance was determined from iv dosing at a 1 mg/kg lose dsD value was calculated from four runs esD value was calculated from two runs.JSD value was calculated from three runs.</td>
        </tr>
    </table>
    <div class="w-100"></div>

    <table class="row table table-bordered" width="500px">
        <tr>
            <td style="background:lightblue" colspan="2">L'able 6.  A ) Summarv ot D'Z3 nhibitorv Activitv ot 4y across Species. (B) Selectivity Profile of 49 against Related Ecto-enzvmes, (C) CD73 Activity ot 49 in a Panel ot Cancer Patient Serums (A)</td>
        </tr>
        
        <tr>
            
            <td>assay</td>
            
            <td>IC50 (nM)</td>
            
        </tr>
        
        <tr>
            
            <td>human recombinant CD73a,c,d</td>
            
            <td>0.17  0.02f</td>
            
        </tr>
        
        <tr>
            
            <td>human plasma CD73b,e</td>
            
            <td>0.38  0.11f</td>
            
        </tr>
        
        <tr>
            
            <td>human cell surface CD73a,c,d</td>
            
            <td>0.21  0.12f</td>
            
        </tr>
        
        <tr>
            
            <td>mouse recombinant CD73a,c,d</td>
            
            <td>1.3±0.068</td>
            
        </tr>
        
        <tr>
            
            <td>mouse plasma CD73b,c</td>
            
            <td>1.2±0.28</td>
            
        </tr>
        
        <tr>
            
            <td>(B)</td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>cancer patient serum</td>
            
            <td>CD73 IC50h (nM)</td>
            
        </tr>
        
        <tr>
            
            <td>HNSCC</td>
            
            <td>0.21</td>
            
        </tr>
        
        <tr>
            
            <td>ovarian cancer</td>
            
            <td>0.15</td>
            
        </tr>
        
        <tr>
            
            <td>TNBC</td>
            
            <td>0.18</td>
            
        </tr>
        
        <tr>
            
            <td>esophageal</td>
            
            <td>0.10</td>
            
        </tr>
        
        <tr>
            
            <td>(C)</td>
            
            <td></td>
            
        </tr>
        
        <tr>
            
            <td>enzyme</td>
            
            <td>IC50 (nM)</td>
            
        </tr>
        
        <tr>
            
            <td>CD39i</td>
            
            <td>>10,000</td>
            
        </tr>
        
        <tr>
            
            <td>ENTPD2</td>
            
            <td>>10,000</td>
            
        </tr>
        
        <tr>
            
            <td>ENTPD3</td>
            
            <td>>10,000</td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="2"></td>
        </tr>
    </table>
    <div class="w-100"></div>

    <table class="row table table-bordered" width="500px">
        <tr>
            <td style="background:lightblue" colspan="6">Table 7. Plasma Protein Binding Profile of 49a</td>
        </tr>
        
        <tr>
            
            <td>species</td>
            
            <td>mouse</td>
            
            <td>rat</td>
            
            <td>dog</td>
            
            <td>monkey</td>
            
            <td>human</td>
            
        </tr>
        
        <tr>
            
            <td>plasma protein binding</td>
            
            <td>63%</td>
            
            <td>71%</td>
            
            <td>42%</td>
            
            <td>60%</td>
            
            <td>58%</td>
            
        </tr>
        
        <tr>
            
            <td>(% bound)</td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
            <td></td>
            
        </tr>
        
        <tr>
            <td style="background:#cecece" colspan="6">The data were determined at 10 uM concentration of 49 0.42) is most likely responsible for the minimal loss of its CD73 inhibitory activity in the presence of full plasma, which s highly differentiated from other known CD73 inhibitors.42</td>
        </tr>
    </table>
    <div class="w-100"></div>


<div></body>
</html>